Dr. Tripathy on Completing New Assays After Recurrence

Debu Tripathy, MD
Published: Thursday, Aug 18, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, describes that when a patient has a recurrence the standard, if it is feasible, is to complete a new biopsy because the markers may have changed.

Tripathy explains that there will be a change in estrogen and progesterone receptors in approximately 10-20% of cases, with HER2 changes occurring in 5-10%.
Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, describes that when a patient has a recurrence the standard, if it is feasible, is to complete a new biopsy because the markers may have changed.

Tripathy explains that there will be a change in estrogen and progesterone receptors in approximately 10-20% of cases, with HER2 changes occurring in 5-10%.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x